Evaluation Of Risk Factors In Cardiovascular Patients With Diagnosis Of Systemic Lupus Erythematosus (SLE)
Title: Evaluation of risk factors in cardiovascular patients with diagnosis of Systemic Lupus Erythematosus (SLE).
Background: prevalence of cardiovascular risk factors in lupic patients.This study aimed to evaluate the presence of cardiovascular risk factors in patients diagnosed with SLE in a Rheumatology Ambulatory, comparing groups with and without SLE nephritis.
Methods: a quantitative, observational and cross-sectional study was carried out during the period from November 2016 to June 2017. 86 patients were interviewed using specific protocol.
Conclusions: among the cardiovascular risk factors evaluated, systemic hypertension was more frequent in SLE patients (33.7%), followed by smoking (17.4%) and diabetes mellitus (5.8%). There was, however, no difference between the frequency of these comorbidities in the groups with and without lupus nephritis.
2 – Sinicato NA, Cardoso PAS, Appenzeller S. Risk factors in cardiovascular disease in systemic lupus erythematosus. Curr Cardiol Rev. 2013 Feb;9(1):15-9.
3 – Couser WG. Patogênese e tratamento da glomerulonefrite - uma atualização. J Bras Nefrol 2016;38(1):107-122.
4 - lori TO, Enofe N, Oommen A, Cobb J, Navarrete J, et al.. Comparison of Outcomes between Individuals with Pure and Mixed Lupus Nephritis: A Retrospective Study. Research Article, Published online: jun, 2016.
5 - Urowitz MB, Ibañez D, Su J, Gladman DD. Modified Framingham Risk Factor Score for Systemic Lupus Erythematosus. J Rheumatol. 2016 May;43(5):875-9.
6 - Yap DY, Tang CS, Ma MK, Lam MF, Chan TM. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant. 2012 Aug;27(8):3248-54.
7 - Shaharir SS, Mustafar R, Mohd R, Mohd Said MS, Gafor HA. Persistent hypertension in lupus nephritis and the associated risk factors. Clin Rheumatol. 2015 Jan;34(1):93-7.
8 - Atukorala I, Weeratunga P, Kalubowila J, et al. Cardiovascular risk in lupus nephritis: Do renal disease-related and other traditional risk factors play a role? Saudi J Kidney Dis Transpl 2015;26(3):526-535.
9 - Tselios K, Koumaras C, Gladman DD, Urowitz MB. Dyslipidemia in systemic lupus erithematosus: just another comorbidity? Semin Arthritis Rheum. 2016 Apr;45(5):604-10.
10 - Farschou M. et al. High Risk of Ischemic Heart Disease in Patients with Lupus Nephritis. The Journal of Rheumatology Nov2011, 38 (11) 2400-5.
11 - Petri M. et al. Derivation and Validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheum. 2012 Aug;64(8):2677-86.
12 - Balsamo S, Nascimento DC, Tibana RA, Santana FS, Mota LMH, Santos-Neto LL. The quality of life of patients with lupus erythematosus influences cardiovascular capacity in 6-minute walk test. Rev. Bras. Reumatol. 2013. Feb; 53( 1 ): 81-87.
13 - Medeiros MM, Xavier de Oliveira IM, Ribeiro AT. Prevalence of metabolic syndrome in a cohort of systemic lupus erythematosus patients from Northeastern Brazil: association with disease activity, nephritis, smoking, and age. Rheumatol Int. 2016 Jan;36(1):117-24.
14 – Lima JE et al. Avaliação do polimorfismo genético pvu II do receptor de lipoproteína de baixa densidade (RLDL) em pacientes com lúpus eritematoso sistêmico. Semina: Ciências Biológicas e da Saúde, Londrina. 2015 Ago; 36(1): 109-22.
15 – Malachias MVB et al. 7a Diretriz Brasileira de Hipertensão Arterial. Arq Bras Cardiol 2016 Set; 107(3).
16 - Kdigo 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, v. 3, jan, 2013. Disponível em: http: // www.kidney-international.org. Acessado em: 12 agosto 2017.
17 - Lotufo P. O escore de risco de Framingham para doenças cardiovasculares. revistadc 18dez.2008; 87(4):232-7.
18 - Kidney International Supplements (2012) 2, 259–274;. Disponível em: http: // www.kidney-international.org. Acessado em: 12 agosto 2017.
19 – Stone NJ et al. 2013 ACC / AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul 1;63:2889-934.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright policies & self-archiving
We are a RoMEO green journal.
Author's Pre-print: author can archive pre-print (ie pre-refereeing)
Author's Post-print: author can archive post-print (ie final draft post-refereeing)
Publisher's Version/PDF: author can archive publisher's version/PDF
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access and Benefits of Publishing Open Access).
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
Articles are published Under License of Creative Commons Attribution 4.0 License ©